Problem
Why GGTI Exists
Our Approach
Four pillars:
• Weekly Global Collaboration
• Capacity Building
• Policy & Regulation
• Technology Development
Focus Areas
Focus Areas
- Community Engagement
- Capacity Building
- Regulatory Development
- Technology Innovation
Our Story
‘maybe in another 10–15 years’
too many times. After failing to meaningfully engage gene therapy developers for access to treatment for her patients with sickle cell and HIV in Uganda, she discovered a TEDx talk about how to make this work. All it took was one phone call to find Dr. Jennifer Adair and get connected to a host of others anxious about access to transformative treatments. This grassroots group founded GGTI to ensure equitable access becomes part of innovation from day one.
Our Reach.
Incredible Science. Unequal Access.
Although dozens of cell and gene therapies are in development or already approved, the overwhelming majority of patients remain excluded because of cost, infrastructure and geography. Most low- and middle-income countries have been left out of the clinical development pipeline.
people living with HIV worldwide
of people living with HIV and SCD live in Africa
children born with sickle cell disease annually
or fewer eligible patients have access to gene therapy
The number of cell and gene therapy trials for sickle cell or HIV which have taken place around the world
The number of cell and gene therapy trials for sickle cell or HIV which have taken place in Africa
Our Causes.
Popular Achievements
JCRC and Makerere University join IMMUNEQUITY, a six-year programme led by Western University and funded by the Government of Canada, to develop, test and manufacture an affordable HIV cure in Uganda and Canada.
Featured Speaker at the 5th Global Sickle Cell Conference (Nigeria)
GGTI member Jimi Olaghere was a featured speaker at the 5th Global Sickle Cell Conference in Nigeria, sharing his remarkable journey from living with sickle cell disease to becoming the first Nigerian successfully treated with CRISPR-based gene therapy.
GGTI Member's Community Artwork Featured on Science Translational Medicine Cover
Artwork emerging from the JABASA Center, supported by GGTI member Moses, was featured on the cover of Science Translational Medicine. The recognition highlights the power of community engagement in connecting patients, researchers, and advocates, demonstrating how art and storytelling can amplify patient voices and bring greater visibility to the communities that stand to benefit from advances in gene therapy.










